« Previous | Next » | All Messages |  GTHA Message Board Home | recommend post |  Ignore Poster

GTHA News GeneThera to Be Subject of Expanded Global Media Campaign

WHEAT RIDGE, Colo.--(BUSINESS WIRE)--GeneThera (OTCBB:GTHA) announces that it will be the main subject of a Media Campaign being led by InvestInItaly.

InvestInItaly has designed a press program that will feature GeneThera and its collaboration with IZSLER as previously announced. The campaign will feature GeneThera and a quote from Dr. Tony Milici, CEO, and be published in various magazines and journals such as Les Echos, Le Monde, Le Figaro, La Tribune, Handelsblatt, L’Express, Investir, Le Pointe, L’usine Nouvelle, Nature, Science, Scrip WP Newsletter, Chemistry Today and New Scientist. Many of these publications have worldwide publication.

Commenting on the Press Campaign, Dr. Tony Milici, CEO of GeneThera said, “We are very happy that GeneThera has been chosen as the subject of this advertising campaign by InvestInItaly. It will be energizing for the Company to have its name in publications throughout the world and to let the worldwide community know of our work and what we are attempting to accomplish with our collaboration with IZSLER.”

ABOUT GENETHERA, INC.:

GeneThera, Inc. is a molecular biotechnology company located in Wheat Ridge, CO. The Company provides genetic diagnostic solutions for the veterinary and agricultural industries with future plans to include the health-care industry. The Company's proprietary diagnostic solution is based on a genetic expression assay, GEA™, a protocol designed to function on a highly automated Fluorogenic PCR platform. This platform enables GeneThera to offer tests that are presently not available from other technologies. The GEA™ is designed for a host of individual diseases, the current priority being Mad Cow Disease; Chronic Wasting Disease, a disease affecting elk and deer in North America; E.Coli 0157:H7; and Johnne's Disease, diseases affecting cattle worldwide. The company is currently focusing on the two molecular laboratories they are planning to open outside the US to treat cattle for Mad Cow Disease and Johnne's Disease. GeneThera has an agreement with Istituto Zooprofilattico Sperimentale della Lombardia e dell'Emilia Romagna to collaborate on scientific research related to the diagnosis of animal transmittable diseases, such as Mad Cow Disease and Scrapie. The other lab will be located in Mexico where they will be focusing on Johnne's Disease.

ABOUT “INVEST IN ITALY”:

As an institutional joint-project between Sviluppo Italia – the National Agency for Enterprise and Inward Investment Development - and the Italian Trade Commission – the Government Agency which promotes the internationalization of Italian companies - InvestInItaly acts as a single reference point for foreign companies looking for winning solutions to expand their business in Italy. Moreover, InvestInItaly represents Italy's national trademark for all promotion activities focused on the country's competitive factors and aimed at encouraging the development of new investment projects in the international business community.

InvestInItaly offers foreign companies a full spectrum of professional services throughout the investment process: from location scouting to the set up phase, from incentives negotiations to Public Administration dealings and after-care services.

"Safe Harbor" Statement: Certain statements in this release are "forward-looking" statements as defined in the Private Securities Litigation Reform Act of 1995. Such statements are subject to numerous risks and uncertainties. Actual results may vary significantly from the results expressed or implied in such statements. Factors that could cause actual results to materially differ from forward-looking statements include, but are not limited to, the Company's ability to meet the terms and conditions required to obtain its project financing, risks and delays associated with product development, risk of market acceptance of new products, risk of technology or product obsolescence, competitive risks, reliance on development partners and the need for additional capital.